Strikingly, decitabine-pretreated CD8+ T cells acquired increased cytolysis activity against tumor cells with anti–PD-1 treatment at different time points and with distinct effector and target ratios (1:1, 1:2, 1:4) (Figure 1B and Supplemental Figure 1, A and B). The gene discussed is PDCD1; the disease is neoplasm.